Table 1.

Baseline characteristics and clinical features of patients according to age category

<55 yr (n=3034)55−64 yr (n=2699)65−74 yr (n=3329)≥75 yr (n=2206)P Value
Age (yr)46.7±6.059.7±2.969.5±2.979.7±4.0<0.001
Men (%)2771 (91.4)2134 (79.2)2061 (62.0)1032 (46.8)<0.001
BMI (kg/m2)25.1±3.524.3±3.123.6±3.222.5±3.6<0.001
Past History
 HTN1041 (34.4)1282 (47.6)1869 (56.4)1259 (57.3)<0.001
 DM601 (19.9)800 (29.7)1111 (33.5)631 (28.7)<0.001
 IHD325 (10.7)424 (15.7)617 (18.6)441 (20.1)<0.001
 Hyperlipidemia357 (11.8)304 (11.3)282 (8.5)142 (6.5)<0.001
 Smoking2429 (80.5)1678 (62.5)1605 (48.5)823 (37.6)<0.001
Initial presentation
 SBP130±28129±29128±29126±31<0.001
 DBP82±2579±1777±1675±18<0.001
 HR78±2277±2377±2179±230.03
 Killip class1.3±0.71.4±0.81.5±0.91.7±1.0<0.001
 LVEF (%)53±1152±1251±1349±13<0.001
Diagnosis<0.001
 STEMI1949 (64.2)1617 (59.9)1864 (56.0)1198 (54.3)
 NSTEMI1085 (35.8)1082 (40.1)1465 (44.0)1008 (45.7)
 PCI2619 (86.5)2309 (85.7)2774 (83.5)1664 (75.6)<0.001
In-hospital mediation
 Aspirin2990 (99.1)2650 (98.7)3268 (98.7)2157 (98.1)0.03
 Clopidogrel2923 (96.9)2583 (96.5)3193 (96.4)2091 (95.1)0.01
 Anticoagulation2294 (76.0)2095 (78.0)2628 (79.4)1718 (78.2)0.01
β-blocker2303 (76.3)1984 (73.9)2435 (73.5)1489 (67.7)<0.001
 ACE inhibitor or ARB2467 (81.7)2152 (80.1)2666 (80.5)1710 (77.8)0.01
 Statin2298 (76.1)1996 (74.3)2411 (72.8)1512 (68.8)<0.001
Prevalence of CKD (ml/min per 1.73 m2)
 mean eGFR88.3±22.277.8±21.167.7±22.357.4±21.0<0.001
<0.001
 eGFR ≥602798 (92.2)2241 (83.0)2255 (67.7)1045 (47.4)
 eGFR 45−59129 (4.3)284 (10.5)597 (17.9)526 (23.8)
 eGFR 30−4432 (1.1)76 (2.8)249 (7.5)402 (18.2)
 eGFR <3075 (2.5)98 (3.6)228 (6.8)233 (10.6)
  • Data are presented as n (%) or mean ± SD. BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; SBP, systolic BP; DBP, diastolic BP; HR, heart rate; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated GFR.